A Phase 1a Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX-002 in Healthy Adult Subjects
Latest Information Update: 13 Sep 2023
At a glance
- Drugs ABX-002 (Primary)
- Indications Adrenomyeloneuropathy; Multiple sclerosis
- Focus Adverse reactions; First in man
- Sponsors Autobahn Therapeutics
- 11 Sep 2023 Status changed from not yet recruiting to active, no longer recruiting, According to an Autobahn Therapeutics media release.
- 11 Sep 2023 According to an Autobahn Therapeutics media release, dosing is completed in this trial.The company plans to assess and report topline data in the fourth quarter of 2023.
- 05 Nov 2021 Status changed from planning to not yet recruiting.